EGFR and colorectal carcinoma: However, the development of multidrug chemotherapy regimens such as FOLFOX and FOLFIRI and the emergence of molecular targeting drugs such as anti-VEGF antibody and anti-EGFR antibodies have dramatically improved CRC outcomes.